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Abstract
Loxosceles venoms can promote severe local and systemic damages. We have previously reported that
Loxosceles gaucho spider venom causes a severe early thrombocytopenia in rabbits. Herein, we investigated the
in vitro effects of this venom and its sphingomyelinase fraction on the main functions of platelets. Whole venom
and its fraction induced aggregation of both human and rabbit platelets. Aggregation was dependent of plasma
component(s) but independent of venom-induced lysophosphatidic acid generation. There was no increase in
the levels of lactate dehydrogenase during platelet aggregation, ruling out the possibility of platelet lysis.
The increased expression of ligand-induced binding site 1 (LIBS1) induced by L. gaucho venom and its sphingo-
myelinase fraction, as well as of P-selectin by the whole venom, evidenced the activation state of both human
and rabbit platelets. Adhesion assays showed an irregular response when platelets were exposed to the whole
venom, whereas the sphingomyelinase fraction induced a dose-dependent increase in the platelet adhesion to
collagen. These findings evidence that L. gaucho venom and its sphingomyelinase fraction trigger adhesion,
activation, and aggregation of both human and rabbit platelets. Thus, this work justifies the use of rabbits to
investigate Loxosceles venom-induced platelet disturbances, and it also supports research on the role of platelets
in the pathogenesis of loxoscelism.
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Introduction
Spiders belonging to the genus Loxosceles, popularly
known as brown spiders, are widespread from
equatorial to subtemperate regions of the world.1
Envenomation by Loxosceles sp may result in a
necrotizing-hemolytic syndrome, loxoscelism, which
is considered the most important form of araneism in
South America, where the main species of medical
importance are L. laeta, L. intermedia and L. gaucho.2
The hallmark of the loxoscelism is the develop-
ment of a dermonecrotic wound at the bite site, which
is histologically characterized by edema, extensive
intradermal and subcutaneous hemorrhage, polymor-
phonuclear infiltration, thrombus and extravascular
fibrin deposition that progress to an ulterior aspect
of fibrinoid necrosis.1,2,3 Although less frequent,
human accidents may evoke severe systemic distur-
bances, such as intravascular hemolysis and dissemi-
nated intravascular coagulation, which may result in
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renal failure and death.4,5 We have previously veri-
fied that rabbits injected intradermally with L. gaucho
whole venom develop severe early thrombocytope-
nia, but this phenomenon is not related to systemic
loxoscelism since intravascular hemolysis and disse-
minated intravascular coagulation could not be veri-
fied in this experimental model.6
The sphingomyelinase activity of 30-35 kDa
proteins from Loxosceles sp venom has been described
as the main mechanism in the induction of dermone-
crosis, and the mediation of complex and multifactor-
ial processes, such as complement activation and
interactions between venom components and the cell
membrane and/or extracellular matrix.7-10 Among
other effects, Loxosceles venoms and their toxins
exhibiting sphingomyelinase activity induce platelet
aggregation in vitro.11-14 However, it is unknown
whether it could be the result of either agglutination
or platelet lysis. In addition, the effects of Loxosceles
venoms on other platelet functions, such as adhesion
and activation, have not been studied yet.
Thus, in the present study, we investigated the
in vitro actions of L. gaucho whole venom and its
sphingomyelinase fraction on the main functions of pla-
telets: activation, adhesion and aggregation. Moreover,
in order to extrapolate experimental studies in animals
to the human envenomation, and taking into account
that rabbit is the most used experimental animal
model to investigate loxoscelism, we also compared
the effects of L. gaucho venom and its sphingomyeli-
nase fraction on both human and rabbit platelets.
Material and methods
Loxosceles gaucho venom and its
sphingomyelinase35-kDa fraction
Specimens of L. gaucho were collected in São Paulo
State, Brazil. After electrostimulation of the cephalo-
torax region, spider venom extraction was performed
by micropipette aspiration. The venom extracted of
hundred of spiders was pooled and frozen until the
moment of use, as previously described.15
The protein content was determined by the bicinch-
oninic acid assay,16 using bovine serum albumin (BSA)
(Sigma-Aldrich, USA) as standard. The studied fraction
from L. gaucho venom was purified using a Mono-S
column, as reported by Cunha et al.17 This fraction
showed a single band of 35 kDa by SDS-PAGE, and it
was able to induce dermonecrosis in rabbits and exhib-
ited sphingomyelinase activity assayed as described
previously.7
Platelet aggregation assay
Human blood was withdrawn from the brachial vein of
healthy volunteers and then mixed with 3.8% triso-
dium citrate (9:1, v/v). Only donors declaring that they
had not used any drugs known to interfere with platelet
function for at least 14 days earlier were included in
this study. Rabbit blood was withdrawn from the
auricular central artery through a butterfly scalp
needle (21 g) and then added to 3.8% trisodium citrate
(9:1, v/v). For each experiment using human or rabbit
blood, a new collection of blood was carried out.
The procedures involving animals were performed
in accordance with the Guide for the Care and Use
of Laboratory Animals (1996; http://www.nap.edu/
readingroom/books/labrats/) and they were approved
by the Ethical Committee for the Use of Animals at
Butantan Institute (process number 129/2003).
Platelet-rich plasma (PRP) or washed platelets
were obtained from fresh blood samples of both spe-
cies as described previously.18 Briefly, PRP was
obtained after blood centrifugation (190 g) for 20 min
at room temperature. Washed platelets were obtained
from PRP through sequential washings in Tyrode’s
solution containing prostaglandin PGE1 (Sigma-
Aldrich, USA) and subsequent centrifugations (1900
g/15 min) at room temperature. Final platelet count
in PRP or washed platelets was adjusted to 300 
109/L. Platelet aggregation was performed in a
chrono-log lumiaggregometer (model 560VS) by the
method of Born19 and results were expressed in per-
centage of change in light transmittance.
Whole venom or fraction was diluted in saline
solution, and then 10 mL of whole venom (20 or
40 mg/mL for human or rabbit platelets, respectively,
final concentration) or sphingomyelinase fraction (2 or
4 mg/mL for human or rabbit platelets, respectively,
final concentration) were added to 400 mL of PRP.
The intensity of platelet aggregation was measured for
10 min. The positive control consisted of human or
rabbit PRP incubated with collagen (Chrono-log, USA)
in a final concentration of 2 or 4 mg/mL, respectively.
As it is possible that venom sphingomyelinases
act on lysophasphatidylcholines (LPC) to generate lyso-
phosphatidic acid (LPA), which is known to mediate
platelet activation through the stimulation of the
LPA1 and LPA3 receptors,
20 the participation of the
LPA pathway in the platelet aggregation induced by
L. gaucho venom was investigated. Human and rabbit
PRP were incubated with both venom (in the same con-
centrations described above) and dioctanoylglycerol
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pyrophosphate (DGPP 8:0; Avanti Polar Lipids, USA),
a selective antagonist of the LPA1 and LPA3 recep-
tors,20 in the concentrations of 20 to 40 mM; 1-
acyl(20:4) glycerophosphate (LPA 20:4; Avanti Polar
Lipids, USA) was used as a positive control (concentra-
tions of 20 to 40 mM) to induce platelet aggregation.
Lactate dehydrogenase leakage
In order to verify platelet lysis induced by the
venom, PRP was incubated with L. gaucho whole
venom as described above. After aggregation, it was
centrifuged at 1900 g for 15 min. The supernatant
was used to determine the leakage of lactate
dehydrogenase (LDH) from platelets, according to
a modification of the method described by Burtis and
Ashwood.21
Flow cytometry of platelets
In order to determine the expression of activation
markers on platelet membrane, human or rabbit PRP
incubated with venom or its fraction was used for
flow cytometry studies. Briefly, 1 volume of 2% par-
aformaldehyde in phosphate buffered saline (PBS, pH
7.4) was added to 1 volume of PRP and then incu-
bated with antibody-saturated solution. The labeling
intensity of fluorescein isothiocyanate-conjugated
(FITC-conjugated) or phycoerythrin-conjugated
(PE-conjugated) antibodies was evaluated in PRP
exposed to L. gaucho venom or its fraction and com-
pared with quiescent or collagen-activated platelets.
The following monoclonal antibodies were employed:
FITC-conjugated anti-rabbit GPIIb-IIIa IgY, which
reacts with both rabbit and human platelets22;
anti-ligand-induced binding site (anti-LIBS1; kind
donation of Dr Mark H Ginsberg, Scripps Research
Institute, La Jolla, USA), an antibody that recognizes
the ligand-induced binding site 1 (LIBS1) of human
GPIIIa following occupation of GPIIb-IIIa by either
fibrinogen or peptides that contain the sequence RGD
or HHLGGAKQAGDV,23 and that also cross reacts
with rabbit GPIIIa22; 12A7 (kind donation of Dr Guy
Reed, Harvard School of Public Health, Boston, USA),
an antibody that specifically reacts with rabbit platelet
P-selectin24; PE-conjugated anti-human CD62P
(Pharmingen, USA), that reacts specifically with
human P-selectin.
Platelets were exposed, under the aggregation
conditions described previously, to venom, its fraction
or collagen (positive control) for 10 min. Quiescent pla-
telets (negative control) remained under agitation for the
same time at 37C. Thereafter, each sample was fixed
with an equal volume of 2% paraformaldehyde in PBS.
Aliquots of fixed platelet suspension (25 mL) were
incubated at room temperature in the dark with: (1)
anti-LIBS1 (25 mL, 40 mg/mL) or (2) 12A7 (25 mL, 20
mg/mL) for 1 hour, and then 2 mL of PE-conjugated goat
anti-mouse IgG (Sigma-Aldrich, USA) was added and
incubated for 1 hour; (3) PE-conjugated anti-human
CD62P (2 mL, 100 mg/mL) for 1 hour; (4) FITC-
conjugated anti-rabbit GPIIb-IIIa IgY (2 mL, 500 mg/
mL) for 2 hours. Samples were analyzed on a
FACSCalibur flow cytometer (Becton Dickinson,
USA). Light scatter and fluorescence data from 10 000
events were collected with all detectors in logarithmic
mode. Data were saved in flow cytometry list mode
files for subsequent analysis in WinMDI software,
version 2.8.
Platelet adhesion assay
Platelet adhesion to collagen was performed in
microplates using a modification of a previously
described method.25 Microplates were coated with
50 mL/well of 40 mg/mL equine collagen Type I
(Chrono-log, USA), diluted in 5 mM acetic acid for
2 hours at 37C. Microplates were then washed two
times by plate inversion with PBS containing 2 mM
MgCl2 (modified PBS). Blocking was carried out
with 2 mg/mL BSA for 1 hour at 37C. After wash-
ing with modified PBS, 40 mL/well of PRP (adjusted
to 75  109/L and 150  109/L platelets for human
and rabbit PRP, respectively) were added to pre-
warmed microplates at 37C, and afterwards 10 mL
of two-fold serial dilutions of venom or its fraction
were added. Plates were incubated for 1 hour under
static conditions in a humidified thermostat at
37C. At the end of the incubation, plates were
washed with PBS and wells were rapidly supplemen-
ted with 150 mL of 0.1 M citrate buffer, pH 5.4,
containing 0.1% Triton X-100 in order to cause
instantaneous lysis of platelets, and 5 mM p-nitro-
phenyl phosphate (Sigma-Aldrich, USA) as substrate
for platelet phosphatases. After incubation at 37C
for 1 hour, the reaction was stopped and the color
was developed by the addition of 100 mL of 2 M
NaOH. The p-nitrophenol produced by the reaction
was measured with a microplate reader at 405 nm
against a blank, a platelet-poor plasma (PPP). The
percentage of adherent cells was calculated on the
basis of a standard curve obtained with known
platelet counts in PRP preparations.
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Statistical analysis
Two-way ANOVA and Tukey test were used to ana-
lyze data and compare the results among the different
groups. Statistical analyses were carried out on
STATATM software version 5.0 and SigmaStat software
version 2.03 (SSPS, USA). Differences with p < 0.05
were considered statistically significant.
Results
The whole venom of L. gaucho spider and its sphingo-
myelinase fraction were able to induce platelet
aggregation when they were exposed to either human
or rabbit PRP (Figure 1). The intensity of this response
was more evident when human PRP was used, since
rabbit platelets required a two-fold higher concentra-
tion of venom to reach a similar extent of aggregation.
When using washed platelets of both species (without
the presence of plasma components), aggregation was
not observed in the presence of either whole venom
or sphingomyelinase fraction.
Dioctanoylglycerol pyrophosphate was able to inhibit
aggregation induced by LPA 20:4, but not that induced
by L. gaucho whole venom (data not shown). Increase
in the levels of LDH during platelet aggregation of
either rabbit or human PRP induced by the whole venom
under conditions of controlled stirring and temperature
was not observed (Figure 2). Since there was no response
to the whole venom, the sphingomyelinase fraction
was not tested in LPA and LDH experiments.
The study of platelet membrane activation markers
by flow cytometry (Figure 3) showed a significant
increase (p < 0.05) in LIBS1 expression in both human
and rabbit platelets exposed to the whole venom and its
sphingomyelinase fraction. On the other hand,
P-selectin expression was increased in human and rab-
bit platelets by exposition to the whole venom, but not
to the sphingomyelinase fraction. Finally, GPIIb-IIIa
expression in platelets of both species was not modi-
fied by either the whole venom or its fraction.
Both human and rabbit platelets adhered with high
affinity to microplates coated with collagen in a
platelet count-dependent manner. Platelet counts of
150  109/L and 75  109/L for rabbit and human
PRP, respectively, corresponded to the optimum
count to be tested for platelet adhesion in the presence
of L. gaucho whole venom or its fraction. The choice
of these platelet counts let us obtain more homoge-
neous results for concentration-response curves. In
the presence of the sphingomyelinase fraction, but not
L. gaucho whole venom, platelet adhesion from both
rabbit and human PRP responded in a concentration-
dependent manner (Figure 4); the percentage increase
in platelet adhesion as a function of the sphingomyeli-
nase concentration was more intense in rabbit PRP
than in human PRP. In spite of an irregular response
caused by the whole venom, platelet adhesion was
more intense when using human PRP than rabbit
PRP (Figure 4).
Figure 1. Platelet aggregation induced by L. gaucho venom
and sphingomyelinase fraction in rabbit and human platelet-
rich plasma (PRP). Human PRP was incubated with 2 mg/mL
of collagen (positive control), 20 mg/mL of whole venom
or 2 mg/mL of sphingomyelinase fraction. Rabbit PRP was
incubated with 4 mg/mL of collagen (positive control), 40 mg /
mL of whole venom or 4 mg/mL of sphingomyelinase fraction.
Data are expressed as mean + SEM (n ¼ 5).
Figure 2. Effect of the incubation of rabbit and human
platelet-rich plasma (PRP) with 20 mg/mL and 40 mg/mL
L. gaucho whole venom, respectively, on lactate dehy-
drogenase (LDH) leakage. Basal levels were assayed in
platelet-poor plasma (PPP) of both species. Data are
expressed as mean + SEM (n ¼ 5).
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Discussion
Loxoscelism is a necrotizing pathological process,
which may cause systemic hemolytic and coagulation
disorders. Loxosceles venoms and their toxins affect a
wide spectrum of substrates as well as disturb diverse
types of cells, such as keratinocytes, endothelial cells,
leukocytes, red cells and platelets.5,26,27 Importantly,
we show herein that L. gaucho venom and its sphingo-
myelinase fraction promote activation, adhesion and
aggregation of both rabbit and human platelets even
in the absence of other cells.
Although the intensity of the aggregation was more
evident in human PRP exposed to the whole venom or
its fraction, since rabbit platelets required a two-fold
higher concentration of venom to reach a similar
extent of aggregation, both human and rabbit platelets
were susceptible to venom- and sphingomyelinase
fraction-induced aggregation. Moreover, LDH levels
in the milieu of platelets exposed to the venom were
not different from basal levels, ruling out the possibil-
ity that the increase in transmittance observed during
aggregation assay of human and rabbit PRP was
caused by platelet lysis. Furthermore, we confirmed
that L. gaucho venom-induced platelet aggregation,
in PRP of both species, only occurs in the presence
of plasma components, such as observed elsewhere
for L. reclusa venom in human PRP.14
The mechanism of platelet aggregation induced by
Loxosceles venoms has been poorly investigated.
In the last decade, it was reported that sphingomyeli-
nases cloned from L. intermedia and L. reclusa
venoms promote LPC hydrolysis to generate
LPA,28,29 which can activate endothelial cells and
leukocytes in inflammatory events.30 This phospholi-
pid can also induce platelet activation and aggrega-
tion.31 Our results suggest that L. gaucho venom-
induced platelet aggregation is not dependent on the
LPA pathway, which depends on the activation of
LPA1 and LPA3 receptors on platelet surface.
20 How-
ever, a potential participation of the LPA pathway in
Loxosceles venom-induced inflammation remains
unknown and requires investigation.
In quiescent human platelets, about 20% of
GPIIb-IIIa complexes are on membranes of the
a-granules and open canalicular system, but depending
on activation intensity, they can be exposed on the
surface membrane.32 Although our results indicate that
there were no differences in GPIIb-IIIa expression under
any treatment, L. gaucho venom and its fraction induced
significant increases in the expression of an important
Figure 3. Expression of platelet membrane activation mar-
kers: ligand-induced binding site (LIBS1); P-selectin; GPIIb-IIIa.
They were analyzed by flow cytometry and expressed in arbi-
trary units of fluorescence (AUF), on rabbit and human
platelets incubated with L. gaucho whole venom and sphingo-
myelinase fraction. Human platelet-rich plasma (PRP) was
incubated with 2 mg/mL of collagen (positive control),
20 mg/mL of whole venom or 2 mg/mL of sphingomyelinase
fraction. Rabbit PRP was incubated with 4 mg/mL of collagen
(positive control), 40 mg/mL of whole venom or 4 mg/mL of
its fraction. Quiescent platelets were used as negative control
for both species. Data are expressed as geometric mean +
SEM (n ¼ 5). *p < 0.05 vs negative control.
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marker of platelet activation - the LIBS1 epitope - on
both human and rabbit platelets. Once platelets are acti-
vated, the GPIIb-IIIa complex suffers a conformational
change and then anti-LIBS1 recognizes the epitope on
the glycoprotein complex.23,33 In addition, L. gaucho
venom-induced increased expression of P-selectin, a
widely used marker of platelet activation,34 confirms the
platelet activation state induced by the venom in both
human and rabbit platelets. Thus, under in vivo condi-
tions, P-selectin may play an important role in venom-
induced inflammation, especially in interactions
between platelets and leukocytes/endothelial cells in the
bite site.35
Loxosceles venoms have been investigated only for
platelet aggregation activity; therefore, the present
work is the first report about the platelet adhesion
induced by a Loxosceles venom. L. gaucho venom
induces a response that is independent of its concentra-
tion, whereas its sphingomyelinase fraction promotes
a dose-dependent increase in platelet adhesion. A plau-
sible explanation for this differential response is
the existence of many components in Loxosceles
venom - e.g., phosphatases, hyaluronidases, phospho-
hydrolases, metalloproteinases-,4,36 which may inter-
fere in platelet adhesion to collagen, thus preventing
the construction of a dose-response curve with the
whole venom. On the other hand, the homogeneity of
the adhesion results obtained with the sphingomyeli-
nase fraction may encourage the use of this active frac-
tion as a tool to future investigations about molecular
mechanisms of platelet adhesion.
Studies about the biological actions of Loxosceles
venoms have some limitations, and one of the most
important is the spider’s small size, which make
possible to obtain only a tiny amount of venom
for research purposes. Besides these difficulties,
comparative studies about the biological effects of
Loxosceles venoms and their toxins are important to
understand and validate the pathophysiological
phenomena occurring in human beings, since certain
kind of cells from different species are affected by
Loxosceles venoms in different ways. For instance,
Loxosceles venoms promote hemolysis in humans9
but not in rabbits, neither in vitro37 nor in vivo.6 Thus,
the rabbit is not a suitable animal model to study
hemolytic disturbances, even though Barreto et al.38
reported that L. gaucho venom affects the resistance
to both osmotic and shear stress of rabbit red cells
in vivo. Regarding platelets, although our results evi-
dence some differences between human and rabbit
platelet sensitivity, platelets in both species presented
a similar general pattern of response when they were
exposed to the loxoscelic venom and its sphingomye-
linase fraction.
The current results are in line with recent insights
about the participation of platelets in inflammation.
Platelet activation, adhesion and aggregation play a
prominent role in homeostasis as well as in
several pathological phenomena. Thus, platelets can
link hemostasis and inflammation through the release
of vasoactive monoamines (e.g., serotonin and
histamine), chemokines (e.g., PF4/CXCL4, RANTES/
CCL5 and CXCL7) and cytokines (e.g., interleukin-
1b), and also through cell-to-cell interactions
elicited by expression of adhesion and immunolo-
gically related molecules (e.g., P-selectin and
Figure 4. Platelet adhesion of rabbit and human platelet-
rich plasma (PRP) exposed to: L. gaucho whole venom;
sphingomyelinase fraction. Concentration-response curves
were analyzed using a fixed platelets count (rabbit: 150 
109/L; human: 75  109/L) and varying concentrations of
whole venom and its fraction. Data are expressed as mean
+ SEM (n ¼ 4). *p < 0.05 vs rabbit platelets.
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CD40L).39-41 Taking into account this evidence and
that Loxosceles venom-induced dermal necrosis
involves hemostatic and inflammatory disturbances
in its pathogenesis, platelets may play a pivotal role
in the dermal necrosis, not only for their participation
in local thrombotic disorders,6 but also for exacerbat-
ing the local inflammatory response induced by the
Loxosceles venom.
In conclusion, our data demonstrate for the first time
that L. gaucho venom and its sphingomyelinase frac-
tion trigger the main platelet functions in both human
and rabbit platelets, thus justifying the use of the rabbit
as an experimental animal model to investigate the pla-
telet disturbances induced by Loxosceles venoms. The
role of platelets in the pathogenesis of loxoscelism
should be addressed in further investigations, which
may help to develop more efficacious therapeutic inter-
ventions following the envenomation.
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